<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report health-related quality of life (HRQL) outcomes assessed using the Functional Assessment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Therapy-<z:hpo ids='HP_0001903'>Anemia</z:hpo> (FACT-An) among 167 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with lenalidomide versus placebo in a randomized phase 3 clinical trial, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-004 </plain></SENT>
<SENT sid="1" pm="."><plain>Mean baseline to 12 week changes in FACT-An Total scores improved following treatment with lenalidomide 5 and 10mg (+5.7 and +5.7, respectively) versus placebo (-2.8) (both p&lt;0.05) </plain></SENT>
<SENT sid="2" pm="."><plain>Clinically important changes in HRQL from baseline were observed at weeks 12, 24, 36, and 48 among RBC-TIâ‰¥26 week responders in both treatment groups </plain></SENT>
<SENT sid="3" pm="."><plain>Lenalidomide treatment may be effective in improving HRQL outcomes </plain></SENT>
</text></document>